Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levoketoconazole randomized withdrawal study in endogenous Cushing's syndrome
NL-OMON46503Phase 3Active, not recruiting
- Sponsor
- Strongbridge Biopharma
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cushing's syndrome comparing Continued levoketoconazole with Placebo withdrawal (2 arms). Started Dec 2018; status: active, not recruiting.
02
Drugs
levoketoconazole
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NL-OMON46503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46503.